<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05032950</url>
  </required_header>
  <id_info>
    <org_study_id>C4671013</org_study_id>
    <secondary_id>2021-003590-62</secondary_id>
    <nct_id>NCT05032950</nct_id>
  </id_info>
  <brief_title>Drug-Drug Interaction Study to Estimate the Effect of PF-07321332/Ritonavir and Ritonavir on Midazolam in Healthy Participants</brief_title>
  <official_title>COVID-19: A PHASE 1, OPEN-LABEL, 3-TREATMENT, 6-SEQUENCE, 3-PERIOD CROSSOVER STUDY TO ESTIMATE THE EFFECT OF PF-07321332/RITONAVIR AND RITONAVIR ON THE PHARMACOKINETICS OF MIDAZOLAM IN HEALTHY PARTICIPANTS.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to estimate the effect PF-07321332/Ritonavir and Ritonavir on&#xD;
      Midazolam (a cytochrome P450 [CYP]3A4 substrate) in Healthy Adult Participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 17, 2021</start_date>
  <completion_date type="Anticipated">December 3, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 3, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>This is a Phase I, crossover, 3-treatment, 6-sequence study to evaluate the effect of PF-07321332/ritonavir and ritonavir on the PK of midazolam in healthy participants. Midazolam is a substrate for CYP3A4. A total of approximately 12 healthy male and/or female participants will be enrolled into the study.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of midazolam when administered alone</measure>
    <time_frame>Treatment A: Day 1 pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24 and 36 hour post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of midazolam when administered with PF-07321332/ritonavir</measure>
    <time_frame>Treatment B: Day 5 pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 and 72 hour post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of midazolam when administered alone</measure>
    <time_frame>Treatment A: Day 1 pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24 and 36 hour post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCinf of midazolam when administered with PF-07321332/ritonavir</measure>
    <time_frame>Treatment B: Day 5 pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 and 72 hour post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of midazolam when administered alone</measure>
    <time_frame>Treatment A: Day 1 pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24 and 36 hour post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast of midazolam when administered with PF-07321332/ritonavir</measure>
    <time_frame>Treatment B: Day 5 pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 and 72 hour post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of Participants With Treatment-Emergent Adverse Events (TEAEs) of PF-07321332/Ritonavir</measure>
    <time_frame>Baseline up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Participants With Clinically Significant Change From Baseline in Laboratory Abnormalities of PF-07321332/Ritonavir</measure>
    <time_frame>Baseline up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Participants With Clinically Significant Change From Baseline in Vital Signs of PF-07321332/Ritonavir</measure>
    <time_frame>Baseline up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Change in Electrocardiogram (ECG) Findings of PF-07321332/Ritonavir</measure>
    <time_frame>Baseline up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of midazolam when administered with ritonavir</measure>
    <time_frame>Treatment C: Day 5 pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 and 72 hour post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf of midazolam when administered with ritonavir</measure>
    <time_frame>Treatment C: Day 5 pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 and 72 hour post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUClast of midazolam when administered with ritonavir</measure>
    <time_frame>Treatment C: Day 5 pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 and 72 hour post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Oral Clearance (CL/F) of midazolam when administered alone</measure>
    <time_frame>Treatment A: Day 1 pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24 and 36 hour post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F of midazolam when administered with PF-07321332/ritonavir</measure>
    <time_frame>Treatment B: Day 5 pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 and 72 hour post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Oral Volume of Distribution (Vz/F)) of midazolam when administered alone</measure>
    <time_frame>Treatment A: Day 1 pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24 and 36 hour post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/F of midazolam when administered with PF-07321332/ritonavir</measure>
    <time_frame>Treatment B: Day 5 pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 and 72 hour post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Cmax (Tmax) of midazolam when administered alone</measure>
    <time_frame>Treatment A: Day 1 pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24 and 36 hour post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of midazolam when administered with PF-07321332/ritonavir</measure>
    <time_frame>Treatment B: Day 5 pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 and 72 hour post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Decay Half-Life (t1/2) of midazolam when administered alone</measure>
    <time_frame>Treatment A: Day 1 pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24 and 36 hour post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of midazolam when administered with PF-07321332/ritonavir</measure>
    <time_frame>Treatment B: Day 5 pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 and 72 hour post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Healthy Participants</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Midazolam orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-07321332/ritonavir orally + Midazolam orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ritonavir orally + Midazolam orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>Midazolam administered as a single dose on Day 1</description>
    <arm_group_label>Treatment A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-07321332/ritonavir + Midazolam</intervention_name>
    <description>PF-07321332/ritonavir:&#xD;
Administered orally every 12 hours for a total of 9 doses on Days 1-5&#xD;
Midazolam:&#xD;
Administered orally as a single dose on Day 5</description>
    <arm_group_label>Treatment B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir + Midazolam</intervention_name>
    <description>Ritonavir:&#xD;
Administered orally every 12 hours for a total of 9 doses on Day1-5.&#xD;
Midazolam:&#xD;
Administered orally as a single dose on Day 5</description>
    <arm_group_label>Treatment C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Female participants of childbearing potential must have a negative (urine or serum)&#xD;
             pregnancy test.&#xD;
&#xD;
          2. Body mass index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight &gt;50 kg (110 lb).&#xD;
&#xD;
             -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Positive test result for SARS-CoV-2 infection at the time of Screening or Day -1.&#xD;
&#xD;
          2. Evidence or history of clinically significant hematological, renal, endocrine,&#xD;
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or&#xD;
             allergic disease (including drug allergies, but excluding untreated, asymptomatic,&#xD;
             seasonal allergies at the time of dosing).&#xD;
&#xD;
          3. Clinically relevant abnormalities requiring treatment (eg, acute myocardial&#xD;
             infarction, unstable ischemic conditions, evidence of ventricular dysfunction, serious&#xD;
             tachy or brady arrhythmias) or indicating serious underlying heart disease (eg,&#xD;
             prolonged PR interval, cardiomyopathy, heart failure greater than New York Heart&#xD;
             Association (NYHA) 1, underlying structural heart disease, Wolff Parkinson-White&#xD;
             syndrome).&#xD;
&#xD;
          4. Any condition possibly affecting drug absorption (eg, gastrectomy, cholecystectomy).&#xD;
&#xD;
          5. History of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C;&#xD;
             positive testing for HIV, HBsAg, or hepatitis C virus (HCVAb). Hepatitis B vaccination&#xD;
             is allowed.&#xD;
&#xD;
          6. Other medical or psychiatric condition including recent (within the past year) or&#xD;
             active suicidal ideation/behavior or laboratory abnormality or other conditions or&#xD;
             situations related to COVID-19 pandemic (eg, Contact with positive case, residence, or&#xD;
             travel to an area with high incidence) that may increase the risk of study&#xD;
             participation or, in the investigator's judgment, make the participant inappropriate&#xD;
             for the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Brussels Clinical Research Unit</name>
      <address>
        <city>Brussels</city>
        <state>Bruxelles-capitale, RÃ©gion DE</state>
        <zip>B-1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=C4671013</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 27, 2021</study_first_submitted>
  <study_first_submitted_qc>August 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 2, 2021</study_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug-drug interaction</keyword>
  <keyword>Midazolam</keyword>
  <keyword>COVID-19 (Coronavirus disease 2019)</keyword>
  <keyword>SARS-CoV (severe acute respiratory syndrome coronavirus)</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

